loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Roluperidone

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Roluperidone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Minerva's schizophrenia drug rejected by FDA for 2nd time
    Minerva's schizophrenia drug rejected by FDA for 2nd time

    28 Feb 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/minerva-again-tangled-web-rejection-after-fda-nixes-schizophrenia-drug-2nd-time

    FIERCE BIOTECH
    28 Feb 2024
    Share Share
    Minerva Neurosciences Announces Update on its NDAfor Roluperidone
    Minerva Neurosciences Announces Update on its NDAfor Roluperidone

    10 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/10/2665474/32445/en/Minerva-Neurosciences-Announces-Update-on-its-New-Drug-Application-NDA-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Schizophrenia.html

    GLOBENEWSWIRE
    10 May 2023
    Share Share
    Minerva Neurosciences Announces the NDA Filing for Roluperidone
    Minerva Neurosciences Announces the NDA Filing for Roluperidone

    01 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/01/2658173/32445/en/Minerva-Neurosciences-Announces-the-NDA-Filing-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Schizophrenia.html

    GLOBENEWSWIRE
    01 May 2023
    Share Share
    Minerva Receives Refusal to File Letter from FDA for its NDA for Roluperidone
    Minerva Receives Refusal to File Letter from FDA for its NDA for Roluperidone

    17 Oct 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/10/17/2535492/32445/en/Minerva-Neurosciences-Receives-Refusal-to-File-Letter-from-FDA-for-its-New-Drug-Application-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Schizophrenia.html

    GLOBENEWSWIRE
    17 Oct 2022
    Share Share
    Minerva Submits New Drug Application to FDA for Roluperidone
    Minerva Submits New Drug Application to FDA for Roluperidone

    22 Aug 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/08/22/2502130/32445/en/Minerva-Neurosciences-Submits-New-Drug-Application-to-FDA-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Patients-with-Schizophrenia.html

    GLOBENEWSWIRE
    22 Aug 2022
    Share Share
    FDA Recommends Type C Meeting for Minerva to Discuss Evidence for Roluperidone
    FDA Recommends Type C Meeting for Minerva to Discuss Evidence for Roluperidone

    03 Nov 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/11/03/2326391/32445/en/Minerva-Neurosciences-Announces-FDA-Recommendation-for-Type-C-Meeting-to-Discuss-Evidence-for-Use-of-Roluperidone-as-Monotherapy-for-the-Treatment-of-Negative-Symptoms-in-Patients-.html

    GLOBENEWSWIRE
    03 Nov 2021
    Share Share